Status:
TERMINATED
Salt and TH-17 in Healthy Human Subjects
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Th17 Helper Immune Cells
Autoimmunity
Eligibility:
MALE
18-45 years
Phase:
NA
Brief Summary
The overall goal of this study is to evaluate the association between sodium and TH17 cells in human subjects. The subjects will have levels of TH-17 and various hormones measured on low salt diet, lo...
Detailed Description
In recent years, dietary sodium intake has dramatically increased and has been shown to play an active role in a number of detrimental diseases including hypertension and cardiovascular complications....
Eligibility Criteria
Inclusion
- We will seek normal, healthy volunteers age 18-45 years. Participants must be healthy, BMI 18-25.
- We will first recruit male subjects into the pilot study to fully assess the relationship between immune status and salt intake in the absence of hormonal influences (ovulation and menstruation) to establish a baseline understanding before embarking on such a study in women. We will study healthy women subjects in a subsequent later study.
- Subjects must have normal laboratory values for:
- Complete blood count
- Serum creatinine, sodium, potassium, glucose, liver enzymes
- Urinalysis
- Normal ECG
Exclusion
- We will exclude individuals with:
- Systolic blood pressure \> 140 or \< 90
- Diastolic blood pressure \>90 or \< 60
- Creatinine Clearance is abnormal (MDRD formula)
- Known DM, CHF, CAD, PVD, CVA, MI, or RAS.
- Known autoimmune disease (including thyroid disease, asthma, inflammatory bowel disease, rheumatologic diseases)
- Known neurologic disease (i.e. MS)
- Steroid use (oral or inhaled, chronic or within the past 6 months)
- Significant concomitant medical illnesses (cancer, chronic active immunological conditions, etc.)
- If spot Na \> 30 after low salt diet
- Current excessive etoh (\>10oz/etoh/week)
- Current use of recreational drugs
- Current smokers
- Abnormal labs
- Acute hospitalizations including surgery in the past 6 months
- Chronic use of non-steroidal anti-inflammatory or narcotic medications
- Evidence of ischemia or heart block on screening electrocardiogram (greater than type I-second degree heart block, left bundle branch block, or
- ST-T wave changes in 2 or more contiguous leads)
- Subjects taking any prescription medications (with the exception of birth control pills) or herbal medications will be excluded).
- Ingestion of probiotics within last 3 months
- Antibiotic use within last 3 months
- 1st degree relative with an onset of diabetes or hypertension before the age of 60
- 1st degree relative with autoimmune disease (including thyroid disease, asthma, inflammatory bowel disease, rheumatologic diseases)
Key Trial Info
Start Date :
March 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2019
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT02261688
Start Date
March 1 2014
End Date
August 1 2019
Last Update
June 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115